The U.S. Food and Drug Administration has approved Swedish drug maker Orexo AB’s drug to treat opioid addiction, the company said on Thursday, sending its shares up as much as 14.3 percent in Stockholm.
The tablet, Zubsolv, dissolves under the tongue. It combines the drugs buprenorphine and naloxone and will compete with similar products, Subutex and Suboxone, made by Britain’s Reckitt-Benckiser Group Plc.
Orexo said it expects to launch the drug in the United States around September.
Source: Reuters.com – July 4, 2013